Pharmafile Logo

VJOncology

- PMLiVE

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a bid to protect Remicade

dengue fever mosquito

BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine

The company aims to develop a vaccine candidate and also boost mRNA manufacturing capabilities on the African continent

- PMLiVE

Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels

South Korea-based study found AZ followed by Pfizer boosted antibody levels six-fold compared to two AZ doses

- PMLiVE

AZ’s PNH therapy Ultomiris wins EU backing to expand use for children

The positive recommendation is based on interim results from a phase 3 trial

- PMLiVE

CHMP rejects Kyowa Kirin’s Parkinson’s disease drug

Results of eight main studies of drug were 'inconsistent', according to the CHMP

- PMLiVE

Google’s DeepMind opens ‘breakthrough’ protein database to the world

AI company has mapped the structure of 98.5% of the proteins in the human body

- PMLiVE

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

ARV-471 is currently in a phase 2 trial for the treatment of patients ER-positive, HER2-negative locally advanced or metastatic breast cancer

- PMLiVE

Roche engaged in talks with FDA for Alzheimer’s drug candidate

CEO Severin Schwan told reporters Roche will complete a phase 3 trial of gantenerumab in the second half of 2022

- PMLiVE

One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants

New real-world data from Canada shows vaccine efficacy was lower against milder symptomatic disease with one dose

Investigating the Complexities of the Canadian & Global Health Systems

The Honourable Tony Clement, Co-chair at Reshoring Canada and former Minister of Health, discusses digital transformation, the importance of onshore manufacturing and supply chain operations in Canada, current pharmaceutical regulatory...

Impetus Digital

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links